ExploreWatchlistsPricing
  1. JP-listed companies
  2. Chiome Bioscience Inc.
  3. Financials
  4. Revenue

Chiome Bioscience Inc. (4583)

Market cap
¥7.1B
P/E ratio
Develops antibody drugs for cancer and other diseases using its ADLib® System technology, while providing antibody development services to pharmaceutical companies.
SummaryFinancialsDividendsHistoryOwnershipWorkforce
Period EndRevenue (Million JPY)YoY (%)
Dec 31, 2025593-24.02%
Dec 31, 2024781+14.41%
Dec 31, 2023682+8.19%
Dec 31, 2022631-11.52%
Dec 31, 2021713+48.26%
Dec 31, 2020481+7.43%
Dec 31, 2019448+110.28%
Dec 31, 2018213-18.10%
Dec 31, 2017260+3.05%
Dec 31, 2016252-9.96%
Dec 31, 2015280+50.24%
Dec 31, 2014186-54.81%
Mar 31, 2014413+27.28%
Mar 31, 2013324-48.81%
Mar 31, 2012633+36.71%
Mar 31, 2011463

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)
AI Chat